|
| 37947157 | A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104). | Cancer | 2024 |
| 37712994 | Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs. | Eur J Nucl Med Mol Imaging | 2024 |
| 36223554 | Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. | J Clin Oncol | 2023 |
| 37561583 | Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma. | J Clin Invest | 2023 |
| 37490348 | The evolving landscape of salivary gland tumors. | CA Cancer J Clin | 2023 |
| 37620627 | Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. | Nat Med | 2023 |
| 37503077 | Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors. | Res Sq | 2023 |
| 37643133 | A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma. | Clin Cancer Res | 2023 |
| 37339176 | Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity. | Cancer Res | 2023 |
| 37171634 | The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients. | Eur J Nucl Med Mol Imaging | 2023 |
| 36753744 | Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer. | Cancer Res | 2023 |
| 36780190 | Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy. | Clin Cancer Res | 2023 |
| 36689229 | Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma. | JAMA Netw Open | 2023 |
| 36841437 | Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma. | Mod Pathol | 2023 |
| 36305841 | Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. | CA Cancer J Clin | 2023 |
| 34655408 | Secretory Carcinoma of the Thyroid in a 49-Year-Old Man Treated with Larotrectinib: Protracted Clinical Course of Disease Despite the High-Grade Histologic Features. | Head Neck Pathol | 2022 |
| 35536733 | Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. | Oncologist | 2022 |
| 35521657 | A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. | Thyroid | 2022 |
| 35867947 | Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). | J Clin Oncol | 2022 |
| 36367724 | Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. | JAMA Netw Open | 2022 |
| 36165724 | Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise. | Cancer J | 2022 |
| 35192411 | Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). | J Clin Oncol | 2022 |
| 35045748 | Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. | Thyroid | 2022 |
| 35274388 | American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. | Head Neck | 2022 |
| 35034042 | Head and Neck Acinic Cell Carcinoma: A New Grading System Proposal and Diagnostic Utility of NR4A3 Immunohistochemistry. | Am J Surg Pathol | 2022 |
| 34963694 | ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing. | Mod Pathol | 2022 |
| 35339025 | Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies. | Oral Oncol | 2022 |
| 34635506 | Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. | Mol Cancer Res | 2022 |
| 32822275 | Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. | J Clin Oncol | 2021 |
| 33893750 | Diagnostic discrepancy in second opinion reviews of primary epithelial neoplasms involving salivary gland: An 11-year experience from a tertiary referral center focusing on useful pathologic approaches and potential clinical impacts. | Head Neck | 2021 |
| 33586179 | Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer center. | Int J Cancer | 2021 |
| 33890869 | Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. | Endocr Relat Cancer | 2021 |
| 33750196 | Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations. | J Clin Oncol | 2021 |
| 34902824 | NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022. | J Natl Compr Canc Netw | 2021 |
| 34585389 | Therapeutic strategies for systemic therapies of human papillomavirus-related oropharyngeal cancer. | J Surg Oncol | 2021 |
| 34597118 | Androgen Receptor Pathway in Salivary Gland Cancer. | J Clin Oncol | 2021 |
| 33429428 | Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. | J Natl Cancer Inst | 2021 |
| 33318036 | SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. | Cancer Discov | 2021 |
| 32557577 | Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. | Cancer | 2020 |
| 32097509 | Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. | Cancer | 2020 |
| 31680360 | Dynamic contrast-enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers. | NMR Biomed | 2020 |
| 31678634 | A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. | Int J Radiat Oncol Biol Phys | 2020 |
| 32639615 | The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. | Cancer | 2020 |
| 32213539 | HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers. | Cancer Discov | 2020 |
| 32548289 | Computational Modeling of Interstitial Fluid Pressure and Velocity in Head and Neck Cancer Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Feasibility Analysis. | Tomography | 2020 |
| 32433161 | Laboratory-Proven Asymptomatic SARS-CoV-2 (COVID-19) Infection on 18F-FDG PET/CT. | Clin Nucl Med | 2020 |
| 30643254 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types. | Nat Genet | 2019 |
| 30256977 | Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. | J Clin Endocrinol Metab | 2019 |
| 31178218 | Sex disparities in salivary malignancies: Does female sex impact oncological outcome? | Oral Oncol | 2019 |
| 31237963 | The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. | Histopathology | 2019 |